What do you consider the biggest challenge that the pharma/
biopharma industry currently faces?
Publication: Pharma's AlmanacPublished: June 24, 2022
Raj Indupuri, Chief Executive Officer, eClinical Solutions
The reliance on manual and siloed processes across all areas of drug development continues to hold the life sciences industry back. We have seen remarkable progress over the last two years in accelerating digital transformation in clinical development, but there remain significant opportunities to take the volumes of new data streams available in trials and turn them into insights and evidence about new therapies exponentially faster. The process of clinical development continues to be too slow and too costly to allow the industry and patients to fully benefit from the coming wave of immunotherapies that have the opportunity to transform human health. Adopting new technologies, digital trial models, and analytics and AI at scale to keep up with the scientific breakthroughs that are coming remains our biggest challenge.
A technologist with over 25 years of industry experience, Raj Indupuri is responsible for establishing the eClinical Solutions vision and future-looking technology strategy. He is deeply passionate about fostering innovation to revolutionize the Life Sciences industry with ground-breaking technologies that will modernize clinical trials and bring treatments to patients faster. As an industry veteran who has been part of the evolution of Life Sciences and clinical data management for over two decades, Raj has an astute business vision to realize the digital future and enable progress and potential with data and analytics at the core of the company’s innovative products and solutions. Raj is responsible for the overall direction and management of the company and is a Mechanical Engineer with an MBA from Boston University who firmly believes data is the new fuel that will drive human progress.
Contact UsFill out the form below to schedule a demo and/or speak to an eClinical Solutions representative to learn more about elluminate.